Ganga Pharmaceuticals Limited has announced the re-appointment of its Managing Director following a board meeting held on March 10, 2026. The pharmaceutical company's board approved the extension of Mr. Bharat Brijmohan Sharma's tenure for another three-year term, demonstrating confidence in his leadership capabilities.

Board Decision and Regulatory Compliance

The Board of Directors approved the re-appointment based on recommendations from both the Nomination and Remuneration Committee and the Audit Committee. The decision was made during a board meeting that commenced at 4:00 p.m. and concluded at 4:30 p.m. on March 10, 2026. The company has filed the necessary intimation pursuant to Regulation 30 of the SEBI Listing Regulations.

Leadership Profile and Experience

Mr. Bharat Brijmohan Sharma brings substantial industry expertise to his continued role as Managing Director. According to the company's disclosure, he possesses over 35 years of experience in Business and Pharma Industry, providing valuable leadership for the pharmaceutical company's operations.

Corporate Governance and Compliance

The company has confirmed that Mr. Sharma is not debarred from holding the office of Director by virtue of any SEBI order or order of any other authority. This compliance disclosure ensures adherence to regulatory requirements for director appointments and maintains transparency with stakeholders.

Family Connections and Board Structure

The disclosure reveals family connections within the company's leadership structure. Mrs. Srijna Sharma, who serves as a Whole-time Director of the Company, is the spouse of Mr. Bharat Brijmohan Sharma. This relationship has been transparently disclosed as part of the regulatory requirements.

Next Steps and Shareholder Approval

While the Board of Directors has approved the re-appointment, the decision remains subject to approval from the company's members. The re-appointment will take effect from April 01, 2026, marking the beginning of Mr. Sharma's extended three-year tenure as Managing Director of Ganga Pharmaceuticals Limited. The information has been made available on the company's website at www.ayurvedganga.com .

Ganga Pharmaceuticals Limited , a company specializing in Ayurvedic products, has released its unaudited financial results for the half-year ended September 30, 2025. The company reported a decrease in both revenue and profit compared to the same period last year.

Financial Performance

The company's financial performance for the first half of FY2026 shows a significant decline in key metrics:

The revenue from operations saw a sharp decline of 48.19% year-over-year, dropping from Rs. 263.74 lakhs in H1 FY2025 to Rs. 136.65 lakhs in H1 FY2026. The total income, which includes other income, decreased by 5.59% to Rs. 151.45 lakhs.

Net profit for the period fell by 68.61%, from Rs. 7.90 lakhs in the previous year to Rs. 2.48 lakhs in the current half-year. Consequently, the basic earnings per share (EPS) decreased from Rs. 0.16 to Rs. 0.04.

Warrant Conversion and Capital Structure

During the reporting period, Ganga Pharmaceuticals made significant changes to its capital structure:

• The company converted 10,75,000 warrants into equity shares, raising Rs. 112.88 lakhs.
• Each warrant was converted at Rs. 14 per share (Rs. 10 face value + Rs. 4 premium).
• The paid-up equity share capital increased to Rs. 591.15 lakhs following this conversion.
• Out of the funds raised, Rs. 53.48 lakhs has been utilized for stated purposes, with the balance kept in bank accounts.
• The remaining 7,00,000 warrants were forfeited as warrant holders did not remit the balance consideration within the prescribed time.

Operational Highlights

• The company operates in a single business segment: Ayurveda Business.
• The financial results were reviewed by the Audit Committee and approved by the Board of Directors on November 7, 2025.
• The company's auditors, Banka & Banka Chartered Accountants, conducted a limited review of the financial results and found no material misstatements.

Balance Sheet Overview

As of September 30, 2025, Ganga Pharmaceuticals reported:

• Total assets of Rs. 1,016.21 lakhs, up from Rs. 897.21 lakhs as of March 31, 2025.
• Shareholders' funds increased to Rs. 828.50 lakhs from Rs. 713.14 lakhs.
• Current liabilities stood at Rs. 157.13 lakhs, compared to Rs. 160.31 lakhs at the end of the previous fiscal year.

While the company has strengthened its balance sheet through the warrant conversion, the decline in revenue and profit may be a cause for concern. Investors and stakeholders will likely be watching closely to see how Ganga Pharmaceuticals plans to address these challenges and improve its financial performance in the coming quarters.